Axon Ligands (TM) - alphabetic: [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z]

MK 2206

.2HCl

CAS 1032350-13-2

C25H21N5O.2HCl  MW 480.39

Purity: 99%

Soluble in water and DMSO

Ordering Information:

Cat. No. Axon 1684    Prime Source

Qty1:  5 mg (researchs ample) / €125  $163

Promotion: 2 x 5 mg @ €180  $234

Qty2: 25 mg (research sample) / €425  $553

Promotion: 2 x 25 mg @ €640  $832

Qty3: on request contract research synthesis

Send enquiry to: order@axonmedchem.com

or by fax to: +31-50-3600390.

Contact us for payment and tech support.

Biological Activity:   An orally potent and highly selective non-ATP comeptitive allosteric Akt inhibitor that has nanomolar IC50 values and broad preclinicl anti-tumor activities.   References: online   H Hirai et al. MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo. Mol. Cancer Ther. 2010, 9(7), 1956-1967. [online]   AW Tolcher et al. A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). J. Clin. Oncol. 27:15s, 2009 (suppl; abstr 3503). [online]   R Liu et al. The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway. J. Clin. Endocrinol. Metab. 2011, 96(4), E577-E585. [online]     Chemical Name: 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-8,9-dihydro-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one

MK 2206 | Allosteric AKT inhibitor | Axon Medchem | Axon 1678 | MK2206

Axon Ligands In The Field: